Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer (TNBC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04807192
What this trial is testing

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Centre Hospitalier Universitaire Vaudois 40
Early research (Phase 1)Ended earlyNCT03674827
What this trial is testing

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Who this might be right for
Non-Small Cell Lung CancerTriple-negative Breast Cancer
Pfizer 36
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07376629
What this trial is testing

HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Who this might be right for
TNBC
Huabo Biopharm Co., Ltd. 60
Early research (Phase 1)Ended earlyNCT03579472
What this trial is testing

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
M.D. Anderson Cancer Center 38
Testing effectiveness (Phase 2)Looking for participantsNCT06657222
What this trial is testing

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHNSCCSCLC+3 more
Tubulis GmbH 250
Testing effectiveness (Phase 2)Looking for participantsNCT07394387
What this trial is testing

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Who this might be right for
Triple Negative Breast Cancer (TNBC)
The First Affiliated Hospital with Nanjing Medical University 58
Large-scale testing (Phase 3)UnknownNCT01378533
What this trial is testing

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 100
Testing effectiveness (Phase 2)Study completedNCT04537286
What this trial is testing

First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast Cancer
Fudan University 90
Not applicableLooking for participantsNCT06476119
What this trial is testing

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Who this might be right for
Breast Cancer Stage ITriple Negative Breast Cancer (TNBC)
The Netherlands Cancer Institute 490
Testing effectiveness (Phase 2)Looking for participantsNCT07486089
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)HER2-positive Breast CancerTriple-Negative Breast Cancer (TNBC)
Beijing Biotech 60
Testing effectiveness (Phase 2)Looking for participantsNCT06534762
What this trial is testing

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Who this might be right for
NSCLCSCLCColorectal Cancer+4 more
Zhejiang Provincial People's Hospital 260
Testing effectiveness (Phase 2)Looking for participantsNCT07510802
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Who this might be right for
Breast Cancer (Advanced/Metastatic)HER2-positive Breast CancerTriple-negative Breast Cancer
Beijing Biotech 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06404736
What this trial is testing

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Who this might be right for
Early Breast CancerNeoadjuvant TherapyTNBC, Triple Negative Breast Cancer
Fudan University 73
Large-scale testing (Phase 3)Active Not RecruitingNCT03562637
What this trial is testing

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Who this might be right for
Triple Negative Breast Cancer
OBI Pharma, Inc 575
Testing effectiveness (Phase 2)Study completedNCT03289819
What this trial is testing

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Who this might be right for
Malignant Neoplasm of Breast
Institut fuer Frauengesundheit 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07743632
What this trial is testing

Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

Who this might be right for
Breast CancerTriple Negative Breast Cancer
University of Kansas Medical Center 110
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07103447
What this trial is testing

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

Who this might be right for
Breast Cancer - Female
Shuangyue Liu 54
Not applicableNot Yet RecruitingNCT06798506
What this trial is testing

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 300
Not applicableLooking for participantsNCT06230185
What this trial is testing

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Personalis Inc. 422
Early research (Phase 1)Study completedNCT03719326
What this trial is testing

Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Who this might be right for
TNBC - Triple-Negative Breast CancerOvarian Cancer
Arcus Biosciences, Inc. 35
Next Page